Stockholders Approve 3.5 Million Share Increase for Equity Incentive Plan
VCYT has more than doubled off its 52-week low of $22.61.
Summary
Veracyte stockholders approved an amendment to the 2023 Equity Incentive Plan, increasing the share reserve by 3.5 million shares for future equity awards.
Key Events · Corporate Governance and Compliance · VCYT
-
Equity Incentive Plan Expanded
Stockholders approved an amendment to the 2023 Equity Incentive Plan, increasing the number of shares reserved for issuance by 3,500,000 shares. This follows the proposal outlined in the DEF 14A filed on April 22, 2026.
-
Potential Dilution
The newly authorized shares represent a potential future dilution of approximately $168.2 million based on the current stock price, if fully utilized.
-
Annual Meeting Results
All nine nominated directors were elected, the appointment of Ernst & Young LLP as the independent auditor for 2026 was ratified, and executive compensation was approved on a non-binding advisory basis.
Analysis · VCYT · Industrial Applications And Services
Veracyte stockholders approved an amendment to the 2023 Equity Incentive Plan, adding 3.5 million shares to the pool available for future equity awards. This authorization, while crucial for attracting and retaining talent, represents a substantial potential dilution for existing shareholders. If all authorized shares were issued at the current stock price, it would be equivalent to approximately $168.2 million.
How filings like this one have moved
In the 30 days to Sep 14, 2026, 29.9% of the 1591 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.24%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, VCYT was trading at $48.06 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $3.8B. The 52-week trading range was $22.61 to $50.71. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.